Suppression of human colorectal mucosal prostaglandins: Determining the lowest effective aspirin dose

被引:84
作者
Ruffin, MT
Krishnan, K
Rock, CL
Normolle, D
Vaerten, MA
PetersGolden, M
Crowell, J
Kelloff, G
Boland, CR
Brenner, DE
机构
[1] UNIV MICHIGAN, SCH MED, DEPT FAMILY PRACTICE, ANN ARBOR, MI 48109 USA
[2] UNIV MICHIGAN, SCH MED, CTR COMPREHENS CANC, ANN ARBOR, MI 48109 USA
[3] UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA
[4] DEPT VET AFFAIRS MED CTR, MED SERV, ANN ARBOR, MI USA
[5] E TENNESSEE STATE UNIV, JAMES H QUILLEN COLL MED, DEPT MED, DIV HEMATOL & ONCOL, JOHNSON CITY, TN 37614 USA
[6] MT HOME VA MED CTR, JOHNSON CITY, TN USA
[7] UNIV CALIF SAN DIEGO, DEPT INTERNAL MED, DIV GASTROENTEROL, SAN DIEGO, CA 92103 USA
[8] UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, SAN DIEGO, CA 92103 USA
[9] NCI, DIV CANC PREVENT & CONTROL, CHEMOPREVENT BRANCH, BETHESDA, MD 20892 USA
来源
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1997年 / 89卷 / 15期
关键词
D O I
10.1093/jnci/89.15.1152
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A variety of studies have supported the finding that regular intake of aspirin (acetylsalicylic acid) or nonsteroidal anti-inflammatory agents san affect colorectal cancer carcinogenesis, These agents inhibit the synthesis of prostagiandins, High levels of prostaglandins are observed in colon cancer tissues. Purpose: Experiments were planned to determine the lowest dose of aspirin that can markedly suppress the levels of mucosal prostaglandins E-2 and F-2 alpha in colorectal mucosa and to determine whether a relationship exists between een these levels and plasma levels of both acetylsalicylic acid and its metabolite, salicylic acid. Methods: Healthy men and women aged 18 years or older participated in the study. The participants took a single, daily dose of aspirin (40.5, 81, 162, 324, or 648 mg) or a placebo for 14 days. Colorectal biopsy specimens were taken at baseline, 24 hours after the first dose of aspirin, and 24-30 hours and 72-78 hours after the last, i.e., fourteenth, daily dose of aspirin. The biopsy specimens were assayed for prostaglandins E-2 and F-2 alpha by use of a competitive enzyme immunoassay, Plasma concentrations of acetylsalicylic acid and salicylic acid were determined by use of high-performance liquid chromatography, All P values are two-sided. Results: A total of 65 subjects (10 receiving placebo, groups of 10 each receiving 40.5, 81, 162, or 324 mg of aspirin, and a group of 15 receiving 648 mg of aspirin) completed the protocol. One subject reported unacceptable drug-induced toxic effects and did not complete the protocol; other subjects reported acceptable side effects. The lowest dose to significantly suppress colorectal mucosal prostaglandin E-2 concentrations from baseline at 24 hours after the first dose (by 22.6 %; P = .002) and at 24-30 hours after the last close (by 14.2%; P = .021) nas 162 mg. At 92-78 hours after the last dose, there was significant suppression for subjects receiving 81 mg (by 23.7%; P = .008). The lowest dose to significantly suppress colorectal mucosal prostaglandin F-2 alpha concentrations from baseline at 24 hours after the first dose (by 18.3%; P = .832) was 324 mg, The lowest dose causing a marked reduction in the level of prostaglandin F-2 alpha at 23-30 hours (by 15.1%; P = .003) and 72-78 hours (by 23.0%; P = .0002) after the last dose was 40.5 mg, NO detectable amounts of acetylsalicylic acid or salicylic acid were present in the plasma at any of the biopsy time points. Conclusions: The lowest doses of aspirin taken daily for 14 days to significantly suppress concentrations of colorectal mucosal prostaglandins E-2 and F-2 alpha were 81 and 40.5 mg, respectively. The suppression occurred without detectable amounts of aspirin or salicylic acid in the plasma at the time points studied. On the basis bf these observations, we recommend a single, daily dose of 81 mg of aspirin in future studies of this drug as a chemopreventive agent far colorectal cancer.
引用
收藏
页码:1152 / 1160
页数:9
相关论文
共 61 条
[41]   ASPIRIN USE AND CHRONIC DISEASES - A COHORT STUDY OF THE ELDERLY [J].
PAGANINIHILL, A ;
CHAO, A ;
ROSS, RK ;
HENDERSON, BE .
BRITISH MEDICAL JOURNAL, 1989, 299 (6710) :1247-1250
[42]   ASPIRIN AND NONSTEROIDAL ANTIINFLAMMATORY DRUG-USE AND THE RISK OF SUBSEQUENT COLORECTAL-CANCER [J].
PELEG, II ;
MAIBACH, HT ;
BROWN, SH ;
WILCOX, CM .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (04) :394-399
[43]   SUBVERSIVE ACTIVITY OF SYNGENEIC TUMOR-CELLS AS AN ESCAPE MECHANISM FROM IMMUNE SURVEILLANCE AND ROLE OF PROSTAGLANDINS [J].
PLESCIA, OJ ;
GRINWICH, K ;
PLESCIA, AM .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1976, 276 (SEP3) :455-465
[44]   THE SUPPRESSIVE EFFECT OF PIROXICAM ON AUTOCHTHONOUS INTESTINAL TUMORS IN THE RAT [J].
POLLARD, M ;
LUCKERT, PH ;
SCHMIDT, MA .
CANCER LETTERS, 1983, 21 (01) :57-61
[45]  
POLLARD M, 1989, CANCER RES, V49, P6471
[46]   EFFECT OF INDOMETHACIN ON INTESTINAL TUMORS INDUCED IN RATS BY THE ACETATE DERIVATIVE OF DIMETHYLNITROSAMINE [J].
POLLARD, M ;
LUCKERT, PH .
SCIENCE, 1981, 214 (4520) :558-559
[47]   INHIBITORY EFFECT OF ASPIRIN ON AZOXYMETHANE-INDUCED COLON CARCINOGENESIS IN F344 RATS [J].
REDDY, BS ;
RAO, CV ;
RIVENSON, A ;
KELLOFF, G .
CARCINOGENESIS, 1993, 14 (08) :1493-1497
[48]  
REDDY BS, 1987, CANCER RES, V47, P5340
[49]  
REDDY BS, 1993, P AM ASSOC CANC RES, V34, pA3319
[50]   LOW-DOSE ASPIRIN THERAPY FOR CHRONIC STABLE ANGINA - A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL-TRIAL [J].
RIDKER, PM ;
MANSON, JE ;
GAZIANO, JM ;
BURING, JE ;
HENNEKENS, CH .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (10) :835-839